Investments

Masco Group is a leading global provider of engineered solutions and services for the life sciences industry, particularly focused on the rapidly growing biologics market. Founded in 1912 and headquartered in Milan, the company is specialized in high-purity water systems, bioprocessing equipment, modular off-site fabricated facilities, and a range of value-added services. With a strong track record of over 100 years, Masco Group has established significant brand recognition, particularly through its brand Stilmas. The company has expanded its portfolio through four strategic acquisitions since 2017, enhancing its capabilities in bioprocessing and modular facilities.
Masco’s solutions are critical to large biopharma companies and contract development and manufacturing organizations (CDMOs) across more than 80 countries. The company operates seven manufacturing facilities located in Europe, North America, and Asia, employing over 800 professionals and generating revenues exceeding €300 million.

Neopharmed Gentili represents the spin-off of the primary care business of Mediolanum Farmaceutici Group and is a leading pharmaceutical company in the Italian market focused on branded prescription drugs in cardiovascular, neurology and allergo-respiratory therapeutic areas, with a portfolio of off-patent and mostly proprietary products. Its flexible and asset-light business model makes Neopharmed Gentili an attractive commercial platform with a proprietary, reliable, and specialized sales force of over 400 pharma representatives.

Biofarma is the global leading player in the development, manufacturing, and packaging of health supplements, medical devices and cosmetics for large Pharma and CPG clients.
Biofarma offers its clients an integrated offer, from market intelligence, R&D and regulatory support, to manufacturing and packaging of finished dosage form products. Biofarma differentiates itself for its capacity to develop and proactively offer its clients innovative solutions by combining differentiated manufacturing technologies, delivery systems, and formulation capabilities. In addition, Biofarma has a strong expertise in probiotics and has an innovative portfolio of Medical Devices, supported by clinical studies and for which it owns dossiers.
As a result of this differentiated positioning, Biofarma is the partner-of-choice of large Pharma and Consumer Health (‘CHCs’) clients for co-development projects requiring strong innovation capabilities, international regulatory capabilities, and manufacturing quality reliability.

Founded in 2010, Inovie has undergone significant external growth to become the leading independent medical diagnostic provider in France and a key player across Southern and Central France specifically. With a strong local footprint of 23 multi-site laboratories spread over seven key regions (Occitanie, Provence-Alpes-Côte-d’Azur, Nouvelle Aquitaine, Auvergne Rhône Alpes, Centre Val de Loire, Pays de la Loire and Bretagne), Inovie’s biologists and more than 6,000 employees deliver high-standard clinical pathology testing to more than 100,000 patients daily. Inovie has also played a leading role in innovation, notably through their work in four areas of specialty: fertility (Inovie Fertilité), genomics (Imagenome), anatomopathology (Inopath) and veterinary services (Inovie Vet).

Dedalus is a global healthcare software company and one of the largest in the world, offering leading solutions covering the entire spectrum of the continuum of care, helping the healthcare organizations to deliver new models of care. Today the company supports over 7,500 healthcare organizations and 5,700 labs and diagnostic centers worldwide, processing its solutions for more than 540 million population worldwide and managing each year more than 4 billion diagnostic results. Today, the group employs more than 7,000 highly skilled qualified people and has the largest software R&D team in the industry in Europe (∼40% of workforce).

Santé Cie is a leading European provider of homecare and outpatient services, trusted by healthcare professionals across diverse therapeutic segments. Each year, the company cares for nearly 500,000 patients, including both children and adults, offering comprehensive support in areas such as infusion therapy, nutrition, insulin therapy, Parkinson’s disease treatment, respiratory assistance, and wound care. With a dedicated team of 2,700 employees and a network of 120 agencies and centers across France, Germany, and the Netherlands, Santé Cie plays a pivotal role in improving patient outcomes and quality of life